

21 August 2018

NSX Announcement

## CLINICAL TRIAL DEVELOPMENT OF PENAO

As announced on 28 March 2018, Beroni Group (NSX: BTG) ("Beroni Group") has agreed to invest in Cystemix Pty Ltd, a company set up by the University of New South Wales ("UNSW") to advance the clinical development of the potentially ground-breaking anti-cancer drug called PENAO.

Professor Philip Hogg and his colleagues recently gave an update to Beroni's Managing Director, Jacky Zhang and Executive Director & CFO, Peter Wong on the preparatory work for the Phase II clinic trial of the PENAO drug. The project timeline has now been prepared and the project team including the proposed governance structure for Cystemix have been put forward for consideration. The preparations in terms of data analysis, drug manufacturing, selection of Contract Research Organisation and recruitment of staff are now in progress. Based on the project timeline, it is anticipated that the best case scenario is for the Phase II clinical trial to commence in the second half of 2019 with the recruitment of trial patients. The expected duration of the clinical trial will be between 18 and 24 months.

For the Phase II clinical trial, the PENAO drug will be combined with an mTOR inhibitor of the rapalog class which has been demonstrated to be very effective in pre-clinical studies. Three potential trial sites in Sydney, Australia have been identified. Once the trial has commenced the project team will monitor the progress of these trial sites and more trial sites will be added if necessary to accelerate progress of the clinical trial, particularly in jurisdictions with suitable drug regulation, unmet market need and strong existing collaboration. This may include Japan as Beroni has collaboration with a medical group in Japan with extensive hospital and clinical trial facilities. Conducting part of the clinical trials in Japan will strengthen Beroni's application for Japan PMDA's approval of the PENAO drug.

For further information please contact:

Mr Jacky Zhang  
Executive Chairman  
Tel: +86 1851 6931 911  
E: [1710426553@qq.com](mailto:1710426553@qq.com)

Mr Peter Wong  
Executive Director and CFO  
Tel: +61 423 727 580  
E: [pwong@asiainvest.com.au](mailto:pwong@asiainvest.com.au)

### About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group's overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.